Therapy Areas: Inflammatory Diseases
Sintalica Bioscience Announces Key Approval Milestones from the Italian Health Authority
23 November 2022 - - Canadian psychedelic drug discovery company Sintalica Bioscience Corp has received, through the University of Messina, the following authorizations from the Italian Ministry of Health pertaining to its drug development program:

Synthesis and detention of Schedule I drugs - Psilocybin, Psilocin and other derived tryptamines

Cultivation of Psilocybe mushrooms and extraction of tryptamines

Positive opinion for the initiation of safety and efficacy testing

This combination of authorizations are unique in Europe and will allow Sintalica to pursue its full research and development and clinical program at the University's laboratory and related facilities.

Sintalica's approach to psychedelic drug discovery focuses on minimizing hallucinogenic effects while enhancing the psychedelic molecule's strong anti-inflammatory properties.

The company's research and drug development program is focused on neurodegenerative disorders, including SCI-Induced Chronic Neuropathic Pain (Spinal Cord Injury), Fibromyalgia, and Inflammation.

Sintalica has filed three provisional patents for proprietary psychedelic molecules with claims of improved stability, efficacy and bioavailability.

The molecules are being produced in the University's state-of-the-art laboratories, and will be tested for safety and efficacy toward target indications.

Sintalica has an exclusive research partnership with leading Italian research institutes, including the University of Messina and the University of Niccolò Cusano of Rome.

Sintalica's scientific team comprises world-leading scientists in chemistry, pharmacology, biotechnology and neurodegenerative diseases.

Sintalica Bioscience is a Canadian drug discovery company operating through its Italian subsidiary focused on using psychedelics to create breakthrough treatments for neuroinflammatory disorders.

Sintalica has filed three provisional patents for proprietary psychedelic molecules with improved stability and safety profiles, reduced hallucinogenic effects, and enhanced bioavailability.

Sintalica has exclusive partnerships with the University of Messina and the University of Niccolò Cusano, providing access to research facilities, including laboratories, a polyclinic hospital, and a team of world-leading scientists.
Login
Username:

Password:


Related Headlines